Summary
Amgen Inc. announced on October 18, 2006, that its wholly-owned subsidiary, Amgen USA Inc., entered into a Sourcing and Supply Agreement with Fresenius Medical Care Holdings, Inc. This agreement, effective October 1, 2006, and running through December 31, 2011, outlines the terms for Fresenius and its affiliates to purchase Amgen's erythropoietic stimulating proteins, EPOGEN® (epoetin alfa) and Aranesp® (darbepoetin alfa). The core of the agreement is Fresenius' commitment to purchase all of its U.S. and Puerto Rico commercial requirements for these products for managing anemia in hemodialysis patients from Amgen. The agreement includes provisions for discount pricing and rebates, contingent on meeting certain requirements. Amgen states that the financial terms are confidential and not expected to have a material adverse financial impact on the company's earnings. This arrangement solidifies a key supply channel for Amgen's established anemia treatments within the significant dialysis market served by Fresenius.
Key Highlights
- 1Amgen Inc. entered into a Sourcing and Supply Agreement with Fresenius Medical Care Holdings, Inc.
- 2The agreement covers the supply of EPOGEN® (epoetin alfa) and Aranesp® (darbepoetin alfa).
- 3Fresenius has committed to purchase all of its U.S. and Puerto Rico commercial requirements for these products for hemodialysis patient anemia management.
- 4The agreement has a term from October 1, 2006, to December 31, 2011.
- 5The agreement includes provisions for discount pricing and rebates.
- 6Financial terms are confidential and not expected to have a material adverse financial impact on Amgen's earnings.